Associate Professor Andrew Burgess

Principal Research Fellow
ANZAC Research Institute


Website Publications
Lab Website
ORCID

Map

Biographical details

Cancer is a disease of excessive cell division, with cancer cells proliferating uncontrollably, leading to the disruption of normal tissue function and ultimately death. This fact has been central throughout the research career of Dr Andrew Burgess, which began in 1998 as an honours student at the Queensland institute of Medical research. In 1999, he graduated with 1st class honours and received a scholarship to pursue a PhD at the University of Queensland. During his PhD, his research was focused on the characterisation and discovery of a new class of chemotherapy agents called histone deacetylase inhibitors. At the time, very little was known about these compounds, but Dr Burgess research helped identified the mechanisms by which these agents specifically killed both actively dividing and non-dividing cancer cells. Several of these inhibitors have now been approved by the FDA for the treatment of lymphoma.

Upon completion of his PhD in 2004, Andrew was awarded a prestigious NHMRC CJ Martin Post-doctoral fellowship, which took him to the French National research centre (CNRS) in Montpellier, France. Here he continued to explore the basic mechanism of how cells control the division process. This time proved to be a highly productive and exciting time, with Andrew’s work identifying a novel mitotic gene (Greatwall Kinase), which has redefined the understanding of the basic mechanisms controlling cell division. This work was published in world leading journals including PNAS, Science, and EMBO J. Consequently, he was awarded two additional French fellowships, which allowed him to remain in France for 7 years. In recent years, he has developed and published landmark publications utilising quantitative microscopy (biosensors, live cell imaging), mathematical modelling and mass spectrometry. This work recently culminated in the publication of a comprehensive interactive review on the “Phosphoregulation of Mitosis” in Cell, and research publications in J. Cell Science, Science Translation Medicine, Gut and Oncogene. He has 41 publications, a h-index of 21 and has been cited over 2545 times.

In 2012, Andrew received a prestigious 5-year Future Research Leader Fellowship from the Cancer Institute NSW. This allowed him to return to Sydney, Australia and establish his own independent research group at the newly built Kinghorn cancer centre in the Garvan Institute of Medical Research. At the end of 2017, Dr Burgess received an NBCF Investigator Initiated Research Scheme grant and moved his laboratory to the ANZAC Research Institute. His research lab is focused on understanding the mechanisms controlling cell division and how disruption of cell division drives the ability of cancer cells to continuously evolve. Up to 70% of cancer cells have the ability to continually rearrange their DNA, which provides cancer cells with the tools to escape and resist chemotherapy treatments and spread throughout the body, making these cancers the most aggressive and deadly. By understanding the exact mechanisms by which cancer cells achieve this we hope to identify novel targets and treatments for the most aggressive and deadly cancers.`

Associations

  • Sydney Catalyst
  • The Australian Society for Medical Research (ASMR)
  • Australia and New Zealand Society for Cell and Developmental Biology (ANZSCB)
  • The Australian Microscopy and Microanalysis Society (AMMS)
  • The Australian Cell Cycle community

Awards and honours

2018 NBCF Investigator Initiated Research Scheme #IIRS-18-103 (CIA, $398,049/3 years)
2016 Cancer Australia Project Grant #APP1100722 (CIE, $600,000/3 years)
2016 Garvan Post-Doc Symposium – Best Oral presentation
2015 The Patricia Helen Guest Fellowship (Private benefaction $210,000/2 years)
2015 NHMRC Project Grant #APP1081312 (CIE, $614,495/3 years)
2012 Cancer Institute NSW, Future Research Leader Fellowship (CIA, $1.2 million/5 years)
2011 EMBO Conference Scholarship, Cancéropôle du Sud-Ouest France ($600)
2009 Société de Biologie Cellulaire de France (SBCF) Travel Grant ($600)
2009 Foundation Reçherche Médicale (FRM) Post-Doctoral Fellowship ($150,000/2 years)
2007 La Ligue Nationale Contre le Cancer Post-Doctoral Fellowship ($150,000/2 years)
2005 Australian Government NHMRC CJ Martin Biomedical Fellowship ($360,000/2 years)
2003 Queensland Cancer Fund Overseas Travel Scholarship ($3000)
2003 University of Queensland Research Scholar Award
2000 University of Queensland Postgraduate Research Scholarship (UQPRS

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Marini, K., Croucher, D., McCloy, R., Vaghjiani, V., Gonzalez-Rajal, A., Hastings, J., Chin, V., Szczepny, A., Kostyrko, K., Marquez, C., Burgess, A., et al (2018). Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 10(451), eaat3504. [More Information]
  • Rogers, S., McCloy, R., Parker, B., Gallego-Ortega, D., Law, A., Chin, V., Conway, J., Fey, D., Millar, E., O'Toole, S., Cesare, A., James, D., Burgess, A., et al (2018). MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 37(33), 4518-4533. [More Information]
  • Shearer, R., Frikstad, K., McKenna, J., McCloy, R., Deng, N., Burgess, A., Stokke, T., Patzke, S., Saunders, D. (2018). The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia. Molecular Biology of the Cell, 29(13), 1542-1554. [More Information]
  • Charrasse, S., Gharbi-Ayachi, A., Burgess, A., Vera, J., Hached, K., Raynaud, P., Schwob, E., Lorca, T., Castro, A. (2017). Ensa controls S-phase length by modulating Treslin levels. Nature Communications, 8(1), 1-15. [More Information]
  • Burgess, A., Vuong, J., Rogers, S., Malumbres, M., O'Donoghue, S. (2017). SnapShot: Phosphoregulation of Mitosis. Cell, 169(7). [More Information]
  • Szczepny, A., Rogers, S., Jayasekara, W., Park, K., McCloy, R., Cochrane, C., Ganju, V., Cooper, W., Sage, J., Peacock, C., et al (2017). The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene, 36(39), 5544-5550. [More Information]
  • Haupt, S., Vijayakumaran, R., Miranda, P., Burgess, A., Lim, E., Haupt, Y. (2017). The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology, 9(1), 53-61. [More Information]
  • Burgess, A., Chia, K., Haupt, S., Thomas, D., Haupt, Y., Lim, E. (2016). Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 6, 7. [More Information]
  • Rogers, S., McCloy, R., Watkins, D., Burgess, A. (2016). Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. BioEssays, 38(S1), S24-S32. [More Information]
  • Rogers, S., Fey, D., McCloy, R., Parker, B., Mitchell, N., Payne, R., Daly, R., James, D., Caldon, C., Watkins, D., et al (2016). PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 129(7), 1340-1354. [More Information]
  • Rogers, S., Gloss, B., Lee, C., Sergio, C., Dinger, M., Musgrove, E., Burgess, A., Caldon, E. (2015). Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division, 10, 1. [More Information]
  • McCloy, R., Rogers, S., Caldon, E., Lorca, T., Castro, A., Burgess, A. (2014). Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle, 13(9), 1400-1412. [More Information]
  • Burgess, A., Rasouli, M., Rogers, S. (2014). Stressing Mitosis to Death. Frontiers in Oncology, 4, 140. [More Information]
  • Caldon, E., Sergio, C., Burgess, A., Deans, A., Sutherland, R., Musgrove, E. (2013). Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle, 12(4), 606-617. [More Information]
  • McCloy, R., Shelley, E., Roberts, C., Boslem, E., Biden, T., Nicholson, R., Gee, J., Sutherland, R., Musgrove, E., Burgess, A., et al (2013). Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. British Journal of Cancer, 109(12), 3034-3041. [More Information]
  • Wigan, M., Pinder, A., Giles, N., Pavey, S., Burgess, A., Wong, S., Sturm, R., Gabrielli, B. (2012). A UVR-induced G2-phase checkpoint response to ssDNA gaps produced by replication fork bypass of unrepaired lesions is defective in melanoma. Journal of Investigative Dermatology, 132(6), 1681-1688. [More Information]
  • Burgess, A., Lorca, T., Castro, A. (2012). Quantitative live imaging of endogenous DNA replication in Mammalian cells. PloS One, 7(9), 1-7. [More Information]
  • Vigneron, S., Gharbi-Ayachi, A., Raymond, A., Burgess, A., Labbe, J., Labesse, G., Monsarrat, B., Lorca, T., Castro, A. (2011). Characterization of the mechanisms controlling Greatwall activity. Molecular and Cellular Biology, 31(11), 2262-2275. [More Information]

2018

  • Marini, K., Croucher, D., McCloy, R., Vaghjiani, V., Gonzalez-Rajal, A., Hastings, J., Chin, V., Szczepny, A., Kostyrko, K., Marquez, C., Burgess, A., et al (2018). Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Science Translational Medicine, 10(451), eaat3504. [More Information]
  • Rogers, S., McCloy, R., Parker, B., Gallego-Ortega, D., Law, A., Chin, V., Conway, J., Fey, D., Millar, E., O'Toole, S., Cesare, A., James, D., Burgess, A., et al (2018). MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 37(33), 4518-4533. [More Information]
  • Shearer, R., Frikstad, K., McKenna, J., McCloy, R., Deng, N., Burgess, A., Stokke, T., Patzke, S., Saunders, D. (2018). The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia. Molecular Biology of the Cell, 29(13), 1542-1554. [More Information]

2017

  • Charrasse, S., Gharbi-Ayachi, A., Burgess, A., Vera, J., Hached, K., Raynaud, P., Schwob, E., Lorca, T., Castro, A. (2017). Ensa controls S-phase length by modulating Treslin levels. Nature Communications, 8(1), 1-15. [More Information]
  • Burgess, A., Vuong, J., Rogers, S., Malumbres, M., O'Donoghue, S. (2017). SnapShot: Phosphoregulation of Mitosis. Cell, 169(7). [More Information]
  • Szczepny, A., Rogers, S., Jayasekara, W., Park, K., McCloy, R., Cochrane, C., Ganju, V., Cooper, W., Sage, J., Peacock, C., et al (2017). The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer. Oncogene, 36(39), 5544-5550. [More Information]
  • Haupt, S., Vijayakumaran, R., Miranda, P., Burgess, A., Lim, E., Haupt, Y. (2017). The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology, 9(1), 53-61. [More Information]

2016

  • Burgess, A., Chia, K., Haupt, S., Thomas, D., Haupt, Y., Lim, E. (2016). Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 6, 7. [More Information]
  • Rogers, S., McCloy, R., Watkins, D., Burgess, A. (2016). Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. BioEssays, 38(S1), S24-S32. [More Information]
  • Rogers, S., Fey, D., McCloy, R., Parker, B., Mitchell, N., Payne, R., Daly, R., James, D., Caldon, C., Watkins, D., et al (2016). PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. Journal of Cell Science, 129(7), 1340-1354. [More Information]

2015

  • Rogers, S., Gloss, B., Lee, C., Sergio, C., Dinger, M., Musgrove, E., Burgess, A., Caldon, E. (2015). Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells. Cell Division, 10, 1. [More Information]

2014

  • McCloy, R., Rogers, S., Caldon, E., Lorca, T., Castro, A., Burgess, A. (2014). Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle, 13(9), 1400-1412. [More Information]
  • Burgess, A., Rasouli, M., Rogers, S. (2014). Stressing Mitosis to Death. Frontiers in Oncology, 4, 140. [More Information]

2013

  • Caldon, E., Sergio, C., Burgess, A., Deans, A., Sutherland, R., Musgrove, E. (2013). Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle, 12(4), 606-617. [More Information]
  • McCloy, R., Shelley, E., Roberts, C., Boslem, E., Biden, T., Nicholson, R., Gee, J., Sutherland, R., Musgrove, E., Burgess, A., et al (2013). Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. British Journal of Cancer, 109(12), 3034-3041. [More Information]

2012

  • Wigan, M., Pinder, A., Giles, N., Pavey, S., Burgess, A., Wong, S., Sturm, R., Gabrielli, B. (2012). A UVR-induced G2-phase checkpoint response to ssDNA gaps produced by replication fork bypass of unrepaired lesions is defective in melanoma. Journal of Investigative Dermatology, 132(6), 1681-1688. [More Information]
  • Burgess, A., Lorca, T., Castro, A. (2012). Quantitative live imaging of endogenous DNA replication in Mammalian cells. PloS One, 7(9), 1-7. [More Information]

2011

  • Vigneron, S., Gharbi-Ayachi, A., Raymond, A., Burgess, A., Labbe, J., Labesse, G., Monsarrat, B., Lorca, T., Castro, A. (2011). Characterization of the mechanisms controlling Greatwall activity. Molecular and Cellular Biology, 31(11), 2262-2275. [More Information]

To update your profile click here. For support on your academic profile contact .